Literature DB >> 9126700

Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.

Y S Moon1, K C Chung, M A Gill.   

Abstract

Meropenem is a carbapenem antibiotic that appears to be widely distributed in tissues and is eliminated by both excretion and metabolism. Approximately 70% of meropenem is excreted via the kidneys, thus dosage adjustments are required for patients with renal impairment. The pharmacokinetic parameters for meropenem are similar to those for imipenem/cilastatin, with the exception of meropenem's smaller volume of distribution. The urinary recovery of meropenem is as high as that of imipenem in combination with cilastatin, an inhibitor of renal dehydropeptidase. Therefore, unlike imipenem, meropenem can be used without dehydropeptidase inhibitors to obtain a consistently high concentration in the urine without nephrotoxic effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126700     DOI: 10.1093/clinids/24.supplement_2.s249

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.

Authors:  Zubair A Qureshi; Alveena Syed; Lloyd G Clarke; Yohei Doi; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

2.  Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.

Authors:  Hung-Jen Tang; Chi-Chung Chen; Chun-Cheng Zhang; Kuo Chen Cheng; Shyh-Ren Chiang; Yu-Hsin Chiu; Yee Huang Ku; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.

Authors:  Partha Nandy; Mahesh N Samtani; Rachel Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.

Authors:  Neeraj Dhar; Vincent Dubée; Lluis Ballell; Guillaume Cuinet; Jean-Emmanuel Hugonnet; François Signorino-Gelo; David Barros; Michel Arthur; John D McKinney
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

5.  Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 6.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.

Authors:  Iolanda Cirillo; Geert Mannens; Cor Janssen; Marc Vermeir; Filip Cuyckens; Daksha Desai-Krieger; Nicole Vaccaro; L Mark Kao; Damayanthi Devineni; Rebecca Redman; Kenneth Turner
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

9.  Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.

Authors:  Irja Lutsar; Ursula M T Trafojer; Paul T Heath; Tuuli Metsvaht; Joseph Standing; Susanna Esposito; Vincent Meiffredy de Cabre; Clarissa Oeser; Jean-Pierre Aboulker
Journal:  Trials       Date:  2011-09-30       Impact factor: 2.279

10.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.